BioCryst Pharmaceuticals, Inc. announced that ORLADEYO net revenue expected to more than double in 2022 to no less than $250 million; Company expects ORLADEYO to become the market leader in HAE prophylaxis therapy with peak sales of $1 billion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.27 USD | -4.72% |
|
+12.02% | +21.37% |
07-09 | BioCryst Pharmaceuticals Says Orladeyo Approved in Peru | MT |
07-03 | Island Pharmaceuticals Acquiring Clinical-Stage Antiviral Molecule | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.37% | 1.57B | |
+20.03% | 126B | |
+23.61% | 118B | |
+23.26% | 27.87B | |
-18.07% | 20.95B | |
-15.13% | 16.92B | |
-14.81% | 16.18B | |
+9.78% | 14.84B | |
-46.10% | 14.79B | |
+52.34% | 14.08B |
- Stock Market
- Equities
- BCRX Stock
- News BioCryst Pharmaceuticals, Inc.
- BioCryst Pharmaceuticals, Inc. Provides ORLADEYO Net Revenue and Peak Sales Guidance for Full Year 2022